CVKD Cadrenal Therapeutics Inc Forecast, Technical & Fundamental Analysis
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions... Show more
CVKD is expected to report earnings to rise 35.58% to -140 cents per share on August 06
Q2'26
Est.
$-1.41
Q1'26
Beat
by $0.31
Q4'25
Beat
by $0.05
Q3'25
Beat
by $0.08
Q2'25
Missed
by $0.61
The last earnings report on May 07 showed earnings per share of -103 cents, beating the estimate of -135 cents. With 58.38K shares outstanding, the current market capitalization sits at 9.76M.
A.I.dvisor tells us that CVKD and ARDX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CVKD and ARDX's prices will move in lockstep.
CVKD's RSI Indicator climbs out of oversold territory
The RSI Oscillator for CVKD moved out of oversold territory on June 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 21 similar instances when the indicator left oversold territory. In of the 21 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 43 cases where CVKD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 01, 2026. You may want to consider a long position or call options on CVKD as a result. In of 62 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CVKD just turned positive on June 30, 2026. Looking at past instances where CVKD's MACD turned positive, the stock continued to rise in of 33 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CVKD advanced for three days, in of 170 cases, the price rose further within the following month. The odds of a continued upward trend are .
CVKD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVKD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CVKD entered a downward trend on July 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.447) is normal, around the industry mean (20.977). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). CVKD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (367.979).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CVKD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVKD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
